^
Association details:
| Biomarker: | EGFR L833V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P50.07 - Afatinib Treatment Response in Advanced Lung Adenocarcinomas Harboring Uncommon Mutations in Chinese Population
Published date:
08/18/2021
Excerpt:
...TTF was 15.0, 11.7, and 16.6 months in patients with G719X, S768I, and L861Q mutations, respectively. In patients with the rare uncommon mutation, median TTF was 10.0 months and the ORR was 50.0%. Afatinib demonstrated clinical activity across a set type of specific rare mutations, including EGFR L747P, A767_V769dup, and L833V/H835L, with a case of TTF > 1 year.
